Düzce Üniversitesi Araştırma Hastanesi’nde Enfeksiyon Hastalıkları Servisinde Takip Edilen COVID-19 Hastalarının Yatış Süresine Etki Eden Faktörler

Abstract

Amaç: Aralık 2019’da ortaya çıkan ve tüm dünyada pandemiye sebep olan yeni coronavirüs 19 hastalığı (COVID-19), iki yıldan uzun süredir tüm dünyada milyonlarca insanı enfekte etmiştir. Bu çalışmada, COVID-19 tanısı ile hastanede yatan hastaların yatış süresine etki eden faktörlerin incelenmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya Mart-Haziran 2020 tarihleri arasında enfeksiyon hastalıkları servisinde yatan COVID-19 tanılı hastalar dahil edildi. Hastaların demografik özellikleri, vital bulguları, hemogram, üre, kreatin, C-reaktif protein (CRP), alanin aminotransferaz (ALT), aspartat transaminaz (AST), laktat dehidrojenaz (LDH), protrombin zamanı (PT), uluslararası normalleştirilmiş oran (INR), procalsitonin (pct), d-dimer, ferritin, troponin, nötrofil/lenfosit oranı (NLR) trombosit-lenfosit oranı (PLR), monosit-lenfosit oranı (MLR) ve ortalama trombosit hacmi (MPV)-lenfosit oranı (MPVLR), COVID-19 PCR, akciğer görüntüleme bulguları, tedavi ve hastane yatış süreleri retrospektif olarak incelendi. Bulgular: Çalışmamızda hastaların yaş ortalaması 56,51±15,48, kadın erkek oranı 1/1, ortalama yatış süresi 7,58±3,35 gündü. DM, HT ve malignitesi olan hastalarda, favipravir, enoksaparin ve vitamin C desteği alan hastalarda daha uzun hastane yatışı olduğu, uzun süre hastane yatışı olan hastalarda ateş, pct, AST, LDH değerlerinin kısa yatış süresi olan hastalara göre daha yüksek olduğu saptandı. Lenfosit sayısı ve yüzdesi, NLR, monosit sayısı ve MPV/lenfosit oranı yedi günden uzun süre yatan hastalarda anlamlı derecede düşük bulundu. Sonuç: Hastaneye başvuru şikayetlerinin yatış süresini öngörmede etkisiz olduğu saptandı.

Keywords

• CRP
• COVID-19
• d-dimer
• ferritin
• lenfopeni
• yatış süresi

Factors Affecting the Duration of Hospitalization of COVID-19 Patients Followed Up in the Infectious Diseases Service of Düzce University Research Hospital

Abstract

Aim: The new coronavirus-19 disease (COVID-19), which emerged towards the end of 2019 and caused a pandemic all over the world, has infected millions of people all over the world for more than two years. In this study, it was aimed to examine the factors affecting the length of stay of hospitalized patients with the diagnosis of COVID-19. Material and methods: Patients with COVID-19 hospitalized in the infectious diseases service of our hospital between March and June 2020 were included in the study. Demographic characteristics of patients, vital signs, hemogram during, urea, creatine, C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH), prothrombin time (PT), international normalized ratio (INR), procalcitonin (pct), D-dimer, ferritin, troponin, neutrophil/lymphocyte ratio (NLR) platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR) and mean platelet volume (MPV)-lymphocyte ratio (MPVLR), COVID-19 PCR, lung imaging findings, treatment and length of hospital stay were analyzed retrospectively. Results: In our study, the mean age of the patients was 56,51±15,48, the female-male ratio was 1/1, and the mean hospitalization period was 7.58±3.35 days. Longer hospital stay was observed in patients with DM, HT, and malignancy, and patients receiving favipiravir, enoxaparin, and vitamin C supplements. It was determined that fever, procalcitonin, AST, and LDH values were found to be significantly higher in patients with a long hospitalization period than in patients with a short hospitalization period. Lymphocyte count and percentage, NLR, monocyte count, and MPV/lymphocyte ratio were found to be significantly lower in patients hospitalized for more than seven days. Conclusion: It was found that the complaints of admission to the hospital were ineffective in predicting the length of stay.

Keywords

• CRP
• COVID-19
• d-dimer
• ferritin
• lymphopenia
• length of stay

References

1. World Health Organization Corona Disease (COVID-19 Pandemic.https://www.who.int/emergencies/diseases/novel-coronavirus-2019 erişim: 02.08.2022.
2. Barboza JJ, Chambergo-Michilot D, Velasquez-Sotomayor M, Silva-Rengifo C, Diaz-Arocutipa C, Caballero-Alvarado J, et al. Assessment and management of asymptomatic COVID-19 infection: A systematic review. Travel Med Infect Dis. 2021; 41: 102058.
3. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. 2020; 71(15): 889-90.
4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708-20.
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
6. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infec. 2020; 80(6): e14-e18.
7. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020; 323(20): 2052-9.
8. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: a retrospective study. BMJ. 2020; 368: m1091.

9. El Halabi M, Feghali J, Bahk J, Tallon de Lara P, Narasimhan B, Ho K, et al. A novel evidence-based predictor tool for hospitalization and length of stay: insights from COVID-19 patients in New York city. Intern Emerg Med. 2022; 17(7): 1879-89.
10. Çil E, Sezgin Sayiner H. Length of hospital stay and risk factors associated with prognosis in COVID-19 patients: surprising results. Eur Rev Med Pharmacol Sci. 2022; 26(14): 5268-77.
11. Lei Q, Li G, Ma X, Tian J, Wu YF, Chen H, et al. Correlation between CT findings and outcomes in 46 patients with coronavirus disease 2019. Sci Rep. 2021; 11(1): 1103.
12. Yue H, Bai X, Wang J, Yu Q, Liu W, Pu J, et al. Gansu Provincial Medical Treatment Expert Group of COVID-19. Clinical characteristics of coronavirus disease 2019 in Gansu province, China. Ann Palliat Med. 2020; 9(4): 1404-12.